HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2004.037424v1 50/12/2263    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Worsfold, M. Articles by Davie, M. W.J. Search for Related Content PubMed PubMed Citation Articles by Worsfold, M. Articles by Davie, M. W.J. Related Collections Evidence Based Laboratory Medicine and Test Utilization Proteomics and Protein Markers Endocrinology and Metabolism

Assessment of Urinary Bone Markers for Monitoring Treatment of Osteoporosis

¹ Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic and District Hospital, Oswestry, Shropshire, SY10 7AG, United Kingdom.

^aAuthor for correspondence. Fax 44-1691-404056; e-mail mike.worsfold{at}rjah.nhs.uk.

Background: The usefulness of urinary markers of bone turnover in monitoring therapy depends on their within-person variability compared with their responses to therapy. The aim of this study was to assess the performance of two such markers on this basis.

Methods: We measured variation, during a whole year, of cross-linked N-terminal telopeptide of collagen I (NTx) and urinary deoxypyridinoline (DPD) as ratios to creatinine concentration and after log-transformation of the ratios in untreated women stratified into three bone density classes, of which the lowest was osteoporotic. We also measured changes in bone mineral density at the lumbar spine (LSBMD) and hip (FNBMD) in untreated women with normal bones and in those with moderate osteopenia and calculated the reference change value (RCV; or least significant change) at P <0.05 for all of these measures. We made the same measurements on women treated with bisphosphonates, estrogen replacement (HRT), or calcium and examined their individual responses to treatment compared with RCV.

Results: After 12 months on bisphosphonates, LSBMD changed more than RCV (2.55%) in 47% of women compared with 44% of those on HRT and 13% of those on calcium. Response of FNBMD was less. Log NTx (RCV= –28%) responded to bisphosphonates in 78%, regardless of BMD, but less often to HRT (67%). Log DPD (RCV= –30%) responded to bisphosphonates less frequently (31% at 12 months).

Conclusions: NTx has advantages over DPD in monitoring therapy for osteoporosis when mailed urine samples are used.

The following articles in journals at HighWire Press have cited this article:

				J. Skulan, T. Bullen, A. D. Anbar, J. E. Puzas, L. Shackelford, A. LeBlanc, and S. M. Smith Natural Calcium Isotopic Composition of Urine as a Marker of Bone Mineral Balance Clin. Chem., June 1, 2007; 53(6): 1155 - 1158. [Abstract] [Full Text] [PDF]

				A. G.W. Norden, P. Rodriguez-Cutillas, and R. J. Unwin Clinical Urinary Peptidomics: Learning to Walk Before We Can Run Clin. Chem., March 1, 2007; 53(3): 375 - 376. [Full Text] [PDF]

				C. S. Miller, C. P. King Jr., M. C. Langub, R. J. Kryscio, and M. V. Thomas Salivary biomarkers of existing periodontal disease: A cross-sectional study J Am Dent Assoc, March 1, 2006; 137(3): 322 - 329. [Abstract] [Full Text] [PDF]

				M. Di Stefano, F. Formoso, C. Tamone, G. Aimo, G. Mengozzi, S. Bergui, and G. C. Isaia Short-Term Urine Deoxypyridinoline Biological Variability in the First 5 Years after Menopause Clin. Chem., November 1, 2005; 51(11): 2189 - 2192. [Full Text] [PDF]